Overview
Information & Communication

EM SYSTEMS CO.,LTD.

EM Systems develops and sells healthcare IT solutions across three core segments: dispensing pharmacy systems (electronic medication history, reimbursement computer systems), medical clinic systems (electronic medical record systems for clinics), and care/welfare business support systems. The company also provides network-based ASP services enabling information sharing and centralized management across pharmacy groups. Its competitive strength lies in its integrated, user-friendly digital platforms that support DX adoption among pharmacies, clinics, and care facilities throughout Japan.

Market Cap
¥39.0B
US$248M
EV
¥31.3B
US$199M
Stock¥563▲+0.36%
US$1 = ¥157.25 (2026-10-30)
LTM EV/EBITDA
8.5
x
LTM EV/EBIT
12.4
x
LTM PER
25.8
x
LTM PBR
2.0
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-51.0%pt
100
Nov 4, 25 – Oct 30, 26StockTOPIX
MC → EV Bridge
39.0BUS$248MMarket Cap0.41BUS$2.58M+ Debt6.58BUS$41.9M− Cash1.54BUS$9.77M− Inv. Sec.0.04BUS$0.25M+ NCI31.3BUS$199MEV
AI Briefing
EM Systems: integrated healthcare IT across pharmacy, clinic EMR and care platforms, anchored by majority holder Kokkou (37.55%) and strategic partner Medipal (10.20%) FY25/12 revenue ¥23.7B, OP ¥3.7B (15.5% margin), down from FY24/12's ¥24.8B rev / ¥4.5B OP peak EV/EBITDA fwd ~7.0x on ¥4.5B forecast EBITDA — steady healthcare DX exposure with a concentrated, strategic shareholder base
Performance & Balance
Revenue 5Y (¥B)
14.4US$91.8M'21/1216.9US$108M'22/1220.4US$129M'23/1224.8US$158M'24/1223.7US$150M'25/12
EBITDA 5Y (¥B)
2.75US$17.5M'21/123.27US$20.8M'22/123.58US$22.8M'23/125.82US$37.0M'24/124.76US$30.3M'25/12
Net Income 5Y (¥B)
1.83US$11.6M'21/121.89US$12.0M'22/121.96US$12.5M'23/122.43US$15.4M'24/122.45US$15.6M'25/12
Capital Structure
98%
EquityD/E 0.02xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
8.97US$57.0M0.01US$0.03M'21/1210.1US$64.5M0.11US$0.69M'22/1210.4US$66.2M2.57US$16.3M'23/1212.8US$81.3M1.44US$9.15M'24/128.89US$56.5M0.58US$3.71M'25/12
Shareholders
Top 10 hold 71.1%
1
Kokko Co., Ltd.
37.55%
2
MEDIPAL HOLDINGS CORPORATION
10.20%
3
Goldman Sachs International (Standing Proxy: Goldman Sachs Japan Co., Ltd.)
5.26%
4
Goldman Sachs & Co. Regular Account (Standing Proxy: Goldman Sachs Japan Co., Ltd.)
4.98%
5
The Master Trust Bank of Japan, Ltd. (Trust Account)
3.19%
6
Hiromasa KUNIMITSU
2.96%
7
Epson Sales Japan Corporation
2.83%
8
NORTHERN TRUST CO.(AVFC) RE NON TREATY CLIENTS ACCOUNT (The Hongkong and Shanghai Banking Corporation Limited, Tokyo Branch)
2.07%
9
Employee Stock Ownership Association
1.20%
10
Alfresa Holdings Corporation
0.87%
Management
9 officers
Kenji OISHI
Director and Chairman
Feb 2006 Joined the Company; Executive Officer, Head of Sales Division Jun 2006 Managing Director, Executive Officer, Head of Sales Division Nov 2012 Senior Managing Director, Executive Officer, Head of Sales Division Oct 2015 Director, President and COO Jun 2019 Director, President and Executive Officer, COO Jun 2020 Director and Chairman (current) Mar 2023 Representative Director, Good Cycle System Co., Ltd. (current) Jun 2023 Representative Director, Unike Software Research Co., Ltd. (current) Jan 2026 Representative Director, Conduct Co., Ltd. (current)
1958-10-30
Hiromasa KUNIMITSU
Representative Director, President and Executive Officer
Mar 2000 Joined the Company; General Manager, Yimeng Software System Development (Nanjing) Co., Ltd. Jul 2002 Director, Executive Officer, Head of System Design Department Oct 2009 Director, Executive Officer, Fukuoka Branch Manager Jun 2014 Managing Director, Executive Officer, Head of Chain Pharmacy Division Jul 2018 Managing Director, Executive Officer, Head of System Products Business Division Jun 2020 Representative Director, President and Executive Officer (current) Jul 2020 Vice Chairman, Yimeng Software System Development (Nanjing) Co., Ltd. (current) Jul 2020 Vice Chairman, Yimeng Software System Development (Shanghai) Co., Ltd. (current) Jul 2020 Director, EM Technology Research Institute Co., Ltd. (current) May 2024 Director, Good Cycle System Co., Ltd. (current) Mar 2025 Representative Director, Choki Co., Ltd. (current)
1974-06-29
Megumi SEKI
Director, Senior Executive Officer, Head of Administration Division
Aug 2000 Joined the Company Oct 2001 Chief, Accounting Section, General Affairs Department, Administration Division Jul 2004 Chief, Internal Audit Office Apr 2011 Head, Internal Audit Office Jun 2011 Full-time Corporate Auditor Oct 2015 Supervisor, Yimeng Software System Development (Nanjing) Co., Ltd. (current) Oct 2015 Supervisor, Yimeng Software System Development (Shanghai) Co., Ltd. (current) Jun 2017 Executive Officer, Head of Administration Division Jun 2020 Director, Executive Officer, Head of Administration Division Sep 2021 Corporate Auditor, Brick Pharmacy Co., Ltd. (current) Mar 2023 Director, Senior Executive Officer, Head of Administration Division (current) Jun 2023 Director, Unike Software Research Co., Ltd. Mar 2025 Managing Executive Officer, Unike Software Research Co., Ltd. (current) Mar 2025 Corporate Auditor, Choki Co., Ltd. (current) Jan 2026 Corporate Auditor, Conduct Co., Ltd. (current)
1972-09-06
Gen AOTA
Director (Full-time Audit and Supervisory Committee Member)
Sep 2008 Joined the Company; Executive Officer, Head of Administration Division Jun 2009 Director, Executive Officer, Head of Administration Division Oct 2009 Director, Executive Officer, Head of Central Japan Branch Jun 2014 Managing Director, Executive Officer, Head of Administration Division Apr 2016 Managing Director, Executive Officer, Head of Medical Systems Business Division Jul 2018 Managing Director, Executive Officer, Head of Management Planning Division Jun 2020 Director, Senior Managing Executive Officer, Head of Management Planning Division Jul 2020 Director, Senior Managing Executive Officer, Head of Management Infrastructure Reform Division Mar 2024 Corporate Auditor, EM Technology Research Institute Co., Ltd. (current) Jan 2025 Director, Senior Managing Executive Officer Mar 2025 Director (Full-time Audit and Supervisory Committee Member) (current)
1962-03-26
Kozo KUNIMITSU
Director, Senior Adviser
Jan 1980 Representative Director, President Jun 2001 Chairman, Yimeng Software System Development (Nanjing) Co., Ltd. (current) Jun 2011 Chairman, Yimeng Software System Development (Shanghai) Co., Ltd. (current) Feb 2015 Representative Director, Brick Pharmacy Co., Ltd. (current) Oct 2015 Representative Director, Chairman and CEO Jun 2020 Director, Senior Adviser (current)
1945-10-05
Takeshi MIYATA
Director
Mar 1994 Joined Sogo Medical Co., Ltd. Apr 2001 Executive Officer, Head of Pharmacy Business Division, Sogo Medical Co., Ltd. Nov 2003 President and Representative Director, Medicoal Co., Ltd. Apr 2004 Managing Executive Officer, Sogo Medical Co., Ltd. Jun 2004 Managing Director, Executive Officer, Sogo Medical Co., Ltd. Sep 2011 Joined Sugi Holdings Co., Ltd. Mar 2012 Director, Sugi Pharmacy Co., Ltd. Mar 2016 Representative Director, Mediteir Co., Ltd.; Pharmacist (current) Mar 2021 Director, the Company (current)
1964-12-18
Shinobu OKAMOTO
Director (Audit and Supervisory Committee Member)
Oct 2002 Joined Asahi Audit Corporation (currently Azsa LLC) Mar 2013 Opened Shinobu Terado Certified Public Accountant Office; Head (current) May 2013 Outside Corporate Auditor, AIT Co., Ltd. Mar 2022 Director (Audit and Supervisory Committee Member), the Company (current) May 2024 Outside Director, AIT Co., Ltd. (current)
1976-04-14
Miwako KAMEI
Director (Audit and Supervisory Committee Member)
Apr 1991 Assistant, Faculty of Pharmaceutical Sciences, Nihon University Apr 2002 Full-time Lecturer, Faculty of Pharmaceutical Sciences, Nihon University Apr 2006 Professor, Faculty of Pharmaceutical Sciences, Showa University Oct 2010 Professor, Faculty of Pharmaceutical Sciences, Nihon University Jan 2016 Director, Japanese Society of Geriatric Pharmacy (current) Apr 2020 Professor and Dean, Faculty of Pharmaceutical Sciences, Teikyo Heisei University (current) Mar 2022 Director, the Company Jun 2022 Executive Director, Council for Pharmaceutical Education (current) Sep 2022 Director, Japanese Society for Social Pharmacy (current) Nov 2022 Director, Next-Generation Pharmacy Research Group (current) Mar 2024 Director (Audit and Supervisory Committee Member), the Company (current) Mar 2024 Vice Chair, Japanese Society of Medical Pharmacy (current) May 2024 Director, Japanese Society of Pharmaceutical Practice (current) Jun 2024 Managing Director, Japan Association of Private Pharmacy Schools (current)
1964-10-31
Hidenori AKABANE
Director (Audit and Supervisory Committee Member)
Dec 2009 Registered as attorney; Attorney, Chugai Godo Law Office Apr 2013 Part-time Lecturer, Tokyo University of Pharmacy and Life Sciences Feb 2015 Director, Pharmacy Co-creation Future Human Resources Development Organization (current) Mar 2015 Director, Smart Healthcare Association (current) Apr 2015 Part-time Lecturer, Teikyo University Faculty of Pharmaceutical Sciences (current) Oct 2015 Representative Director, Jasread Co., Ltd. (current) Apr 2016 Outside Director, agt Co., Ltd. May 2016 Outside Director, Good Cycle System Co., Ltd. Jun 2018 Outside Director, Sophia Holdings Co., Ltd. (current) Mar 2023 Director, the Company Dec 2024 Attorney, JMP Law Office (current) Mar 2025 Director (Audit and Supervisory Committee Member), the Company (current)
1975-02-21
Large Shareholding Reports
VARECS Partners Limited
2024-05-29
10.50%→11.53%
VARECS Partners Limited
2024-01-11
5.02%→10.50%
VARECS Partners Limited
2023-08-25
5.02%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-08-10
Semi-Annual Securities Report
Period: Jan 2026 – Dec 2026
TDnet
2026-08-10
Q2 Earnings Flash
FY ending Dec 2026
TDnet
2026-07-21
業績予想の修正
FY ending Dec 2026
TDnet
2026-05-14
Q1 Earnings Flash
FY ending Dec 2026
EDINET
2026-03-26
Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2026-02-13
Full-Year Earnings Flash
FY ending Dec 2025
TDnet
2025-11-14
Q3 Earnings Flash
FY ending Dec 2025
TDnet
2025-10-27
業績予想の修正
FY ending Dec 2025
EDINET
2025-08-08
Semi-Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-05-15
Q1 Earnings Flash
FY ending Dec 2025
EDINET
2025-03-28
Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-08-09
Semi-Annual Securities Report
Period: Jan 2024 – Dec 2024
EDINET
2024-05-29
Large Shareholding Report
EDINET
2024-05-14
Quarterly Securities Report
Period: Jan 2024 – Mar 2024
EDINET
2024-03-28
Annual Securities Report
EDINET
2024-01-11
Large Shareholding Report
EDINET
2023-11-10
Quarterly Securities Report
Period: Jul 2023 – Sep 2023
EDINET
2023-08-25
Large Shareholding Report
EDINET
2023-08-09
Quarterly Securities Report
Period: Apr 2023 – Jun 2023
EDINET
2023-05-11
Quarterly Securities Report
Period: Jan 2023 – Mar 2023
EDINET
2023-03-23
Annual Securities Report
Period: Jan 2022 – Dec 2022
EDINET
2022-11-10
Quarterly Securities Report
EDINET
2022-08-09
Quarterly Securities Report
EDINET
2022-05-13
Quarterly Securities Report
EDINET
2022-03-18
Annual Securities Report
EDINET
2021-11-10
Quarterly Securities Report
EDINET
2021-08-10
Quarterly Securities Report
EDINET
2021-05-14
Quarterly Securities Report
EDINETAmended
2021-03-23
Amended Annual Securities Report
EDINET
2021-03-18
Annual Securities Report
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
Ask me!
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →